ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "remission"

  • Abstract Number: 2851 • 2019 ACR/ARP Annual Meeting

    Limiting Factors of Reaching ACR/EULAR Boolean Remission in Early RA Patients Treated According to Current Recommendations

    Nina Sundlisater1, Anna-Birgitte Aga 2, Ulf Sundin 3, Hilde Hammer 1, Till Uhlig 4, Tore Kvien 4, Espen Haavardsholm 4 and Siri Lillegraven 5, 1Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway, 2Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Oslo, Norway, 3Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway. University of Oslo, Oslo, Norway, Oslo, Oslo, Norway, 4Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, 5Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway

    Background/Purpose: Abrogation of inflammation is important to prevent irreversible joint damage and maximize health-related quality of life in early RA patients. The ACR/EULAR Boolean remission…
  • Abstract Number: 2908 • 2019 ACR/ARP Annual Meeting

    Remission in Patients with Rheumatoid Arthritis Receiving Triple Therapy Compared to Biological Therapy – A Swedish Nationwide Register Study

    Hanna Källmark1, Jon Einarsson 2, Jan-Åke Nilsson 3 and Meliha Kapetanovic 2, 1Lund University, Lund, Sweden, 2Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Section of Rheumatology, Lund and Malmö, Sweden, Lund, Sweden, 3Skane University Hospital, Lund and Malmö, Sweden, Lund, Sweden

    Background/Purpose: Current treatment guidelines for rheumatoid arthritis (RA) recommend a treat-to-target approach with early treatment initiation of disease-modifying antirheumatic drugs (DMARDs), most commonly methotrexate (MTX),…
  • Abstract Number: 837 • 2019 ACR/ARP Annual Meeting

    Does Discordance Between Baseline Patient’s and Evaluator’s Global Assessment of Disease Activity Impact Retention and Remission Rates of a First TNF Inhibitor in Patients with Axial Spondyloarthritis? Data from the EuroSpA Research Collaboration Network

    Brigitte Michelsen1, Lykke Midtbøll Ørnbjerg 2, Anne Gitte Loft 3, Tore Kvien 4, Adrian Ciurea 5, Herman Mann 6, Kari K. Eklund 7, Ayten Yazici 8, Maria José Santos 9, Johan Askling 10, Ziga Rotar 11, Bjorn Gudbjornsson 12, Manuel Pombo-Suarez 13, Catalin Codreanu 14, Irene van der Horst-Bruinsma 15, Eirik Kristianslund 16, Michael J. Nissen 17, Karel Pavelka 6, Nina Trokovic 18, Nevsun Inanc 19, Elsa Vieira-Sousa 20, Daniela DiGuiseppe 21, Matija Tomsic 22, Arni Jon Geirsson 23, Ruxandra IONESCU 24, Marleen van de Sande 25, Florenzo Iannone 26, Carlos Sánchez-Piedra 27, Gareth Jones 28, Lise Hyldstrup 2, Merete Lund Hetland 29 and Mikkel Østergaard 30, 1Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark/ Hospital of Southern Norway Trust, Kristiansand, Norway/ Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, 2Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark, Copenhagen, Denmark, 3Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Århus, Denmark, 4Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, 5University Hospital Zürich, Zürich, Switzerland, 6Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, 7ROB-FIN registry, Department of Medicine, Helsinki University and University Hospital, Helsinki, Finland, 8Kocaeli University, Faculty of Medicine, Division of Rheumatology, Kocaeli, Kocaeli, Turkey, 9Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, 10Karolinska Institutet, Stockholm, Sweden, 11UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, 12Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, 13Unit Research, Spanish Society of Rheumatology, Madrid, Spain, 14Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, 15Amsterdam University Medical Center, Amsterdam, Netherlands, 16Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway., Oslo, Norway, 17University Hospital Geneva, Geneva, Switzerland, 18Helsinki University Central Hospital, Helsinki, Finland, 19Marmara University, Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, ISTANBUL, Turkey, 20Rheumatology and Metabolic Bone Diseases, Hospital de Santa Maria - Centro Hospitalar Lisboa Norte, EPE | Rheumatology Research Unit, Instituto de Medicina Molecular - Faculty of Medicine, University of Lisbon, Lisbon Academic Medical Centre, Lisbon, Portugal,, Lisbon, Portugal, 21Clinical Epidemiology Division, Dept of Medicine Solna, Karolinska Institutet,, Stockholm, Sweden, 22Department of Rheumatology, University Medical Center Ljubljana, Slovenia, Ljubljana, Slovenia, 23Centre for Rheumatology Research, University Hospital and Faculty of Medicine, Reykjavik, Iceland, 24SPITALUL CLINIC SFANTA MARIA, Bucharest, 25Amsterdam UMC, Amsterdam, Netherlands, 26Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, 27Research Unit, Spanish Society of Rheumatology, Madrid, Spain, 28University of Aberdeen, Aberdeen, United Kingdom, 29DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, 30Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark

    Background/Purpose: Discordance between baseline patient’s and evaluator’s global assessment of disease activity is common.1 However, the impact of such discordance on retention and remission rates…
  • Abstract Number: 1172 • 2019 ACR/ARP Annual Meeting

    The Relationship Between Subclinical Inflammation and Bone Damage in Patients with Rheumatoid Arthritis Using Multimodality Imaging

    Scott Brunet 1, Peter Salat 2, Glen Hazlewood 3, Klaus Engelke 4, Cheryl Barnabe 3 and Sarah Manske3, 1University of Calgary, Calgary, Canada, 2University of Calgary, Calary, Canada, 3University of Calgary, Calgary, AB, Canada, 4Erlangen University Hospital, Department of Medicine, Erlangen, Germany

    Background/Purpose: Many RA patients in clinical remission have evidence of bone marrow edema (BME) on magnetic resonance imaging (MRI), with radiographic bone damage progression appearing…
  • Abstract Number: 1242 • 2019 ACR/ARP Annual Meeting

    Impact of Smoking Status on Remission in Hidradenitis Suppurativa

    Amil Agarwal 1, Marissa Mangini 1, Derek Jones 1, Catherine Hood 1, Richard Amdur 1 and Victoria Shanmugam2, 1The George Washington University School of Medicine and Health Sciences, Washington, DC, 2George Washington University, Georgetown, DC

    Background/Purpose: Hidradenitis Suppurativa (HS) is an inflammatory disease of the apocrine sweat glands characterized by recurrent abscessing inflammation. The molecular drivers of HS are poorly…
  • Abstract Number: 1282 • 2019 ACR/ARP Annual Meeting

    Female Sex Is a Risk Factor for Failure to Achieve Remission in Polymyositis

    Prasanth Lingamaneni1, Carrie Richardson 2, Soumyasri Kambhatla 3 and Augustine Manadan 2, 1John H. Stroger Hospital of Cook County, Chicago, IL, 2Rush University Medical Center, Chicago, IL, 3John H. Stroger Hospital of Cook County, Chicago

    Background/Purpose: Adults with polymyositis demonstrate wide variability in responses to treatment, and the risk factors for failure to achieve remission in polymyositis are largely unknown. …
  • Abstract Number: 1340 • 2019 ACR/ARP Annual Meeting

    Patterns of Sustained Remission and Subsequent DMARD Tapering in Early Rheumatoid Arthritis: Data from the Canadian Early Arthritis Cohort

    Maria Powell1, Vivian Bykerk 2, Orit Schieir 3, Marie-France Valois 4, Susan J. Bartlett 5, Louis Bessette 6, Gilles Boire 7, Carol Hitchon 8, Edward Keystone 9, Janet Pope 10, Carter Thorne 11, Diane Tin 12 and Glen Hazlewood 1, 1University of Calgary, Calgary, AB, Canada, 2Hospital for Special Surgery, New York City, NY, 3University of Toronto Dalla Lana School of Public Health, Toronto, ON, Canada, 4McGill University, Montreal, Canada, 5McGill University, Montreal, QC, Canada, 6Laval University, Quebec City, QC, Canada, 7Sherbrooke University, Sherbrooke, QC, Canada, 8University of Manitoba, Winnipeg, Canada, 9Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, 10Western University, London, ON, Canada, 11Southlake Regional Health Centre, Newmarket, ON, Canada, 12Southlake Regional Health Centre, Newmarket, Canada

    Background/Purpose: Rheumatoid arthritis (RA) treatment emphasizes aggressive titration of disease-modifying antirheumatic drugs (DMARDs) with the goal of achieving disease remission. This often includes the use…
  • Abstract Number: 611 • 2018 ACR/ARHP Annual Meeting

    Influence of Dose Titration of Concomitant Steroid and Methotrexate during Biologic Therapy in Patients with Rheumatoid Arthritis in Daily Practice Based on the IORRA Cohort

    Yoko Shimizu1, Eiichi Tanaka1, Eisuke Inoue1,2, Kumiko Saka1, Eri Sugano1, Naohiro Sugitani1,3, Moeko Ochiai1, Rei Yamaguchi1, Naoki Sugimoto1, Ayako Nakajima1,3, Katsunori Ikari1, Atsuo Taniguchi1 and Hisashi Yamanaka4, 1Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 2Division of Medical Informatics, St. Marianna University School of Medicine, Kawasaki, Japan, 3Center for Rheumatic Diseases, Mie University Hospital, Tsu city, Japan, 4Institute of Rheumatology, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan

    Background/Purpose: After the introduction of Biological Disease-Modifying Anti-Rheumatic-Drugs (bDMARDs) for the treatment of patients with active rheumatoid arthritis (RA), clinical remission has become an achievable…
  • Abstract Number: 1199 • 2018 ACR/ARHP Annual Meeting

    The Use of Musculoskeletal Ultrasound to Assess Remission in Patients with Rheumatoid Arthritis

    Myriam Allen1, Maggie Larche2 and Karen A. Beattie2, 1Rheumatology, McMaster University, Hamilton, ON, Canada, 2Medicine, McMaster University, Hamilton, ON, Canada

    Background/Purpose: Patients with rheumatoid arthritis (RA) should achieve remission rapidly to avoid irreversible joint sequela. Studies have shown that patients with apparent clinical remission have…
  • Abstract Number: 1282 • 2018 ACR/ARHP Annual Meeting

    Influence of Renal Function on the Velocity of Tophus Resolution and Achievement of Disease Remission in Patients with Chronic Refractory Gout Treated with Pegloticase

    Brian F. Mandell1, Naomi Schlesinger2, N. Lawrence Edwards3, Anthony Yeo4 and Peter E. Lipsky5, 1Rheumatology, Cleveland Clinic, Cleveland, OH, 2Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, 3Rheumatology, University of Florida Health Science Center, Gainesville, FL, 4Horizon Pharma, Lake Forest, IL, 5AMPEL BioSolutions, Charlottesville, VA

    INFLUENCE OF RENAL FUNCTION ON THE VELOCITY OF TOPHUS RESOLUTION AND ACHEIVEMENT OF DISEASE REMISSION IN PATIENTS WITH CHRONIC REFRACTORY GOUT TREATED WITH PEGLOTICASEBackground/Purpose: Impaired…
  • Abstract Number: 1453 • 2018 ACR/ARHP Annual Meeting

    Correlation between Clinical and Ultrasonographic Remission? the Effect of Non-Inflammatory Patient-Based Factors on Different Remission Definitions

    Ummugulsum Gazel1, Sibel Yilmaz Oner2, Gulsen Ozen3, Yasemin Yalçınkaya3, Pamir Atagunduz3, Haner Direskeneli3 and Nevsun Inanc3, 1Rheumatology, Marmara University faculty of Medicine, Istanbul, Turkey, 2Rheumatology, Bakırköy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey, 3Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey

    Background/Purpose: In this study, we aimed to investigate the concordance of ultrasonographic remission with other remission criteria and to show the influence of non-inflammatory patient-induced…
  • Abstract Number: 1496 • 2018 ACR/ARHP Annual Meeting

    Sex Differences in the Achievement of Clinical Remission and Low MRI Synovitis Scores in Rheumatoid Arthritis

    Joshua Baker1, Mikkel Østergaard2, Carson Maynard3, Michael D. George4, Daniel Baker5 and Philip G. Conaghan6, 1Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, 2Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup Copenhagen Center for Arthritis Research, Copenhagen, Denmark, 3Rheumatology, University of Pennsylvania, Philadlphia, PA, 4Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, 5Johnson & Johnson, Spring House, PA, 6University of Leeds, Leeds, UK, Leeds, United Kingdom

    Background/Purpose: Several prior studies have demonstrated poor clinical responses and reduced likelihood of achievement of remission among women with rheumatoid arthritis (RA). We aimed to…
  • Abstract Number: 1930 • 2018 ACR/ARHP Annual Meeting

    Histologic and Transcriptional Evidence of Subclinical Synovial Inflammation in Rheumatoid Arthritis Patients in Clinical Remission

    Dana Orange1, Phaedra Agius2, Edward F. DiCarlo3, Serene Z. Mirza4, Cristina Rozo5, Tania Pannellini5, Mark P. Figgie6, William H. Robinson7, Jackie Szymonifka5, Vivian P. Bykerk5, Laura T. Donlin8 and Susan M. Goodman5, 1Rockefeller University, New York, NY, 2New York Genome Center, New York, NY, 3Laboratory Medicine, Hospital for Special Surgery, New York, NY, 4Rheumatology, Hospital for Special Surgery, New York, NY, 5Hospital for Special Surgery, New York, NY, 6Surgery, Hospital for Special Surgery, New York, NY, 7Stanford University, Palo Alto, CA, 8Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY

    Background/Purpose:   Rheumatoid Arthritis (RA) patients in clinical remission may still develop structural damage that has been attributed to ongoing synovial inflammation, sometimes only detectable…
  • Abstract Number: 2820 • 2018 ACR/ARHP Annual Meeting

    Sustained Clinical Remission after Discontinuation of Infliximab with a Raising Dose Strategy in Patients with Rheumatoid Arthritis (RRRR study): A Randomized Controlled Trial

    Yoshiya Tanaka1, Koji Oba2,3, Takao Koike4,5, Nobuyuki Miyasaka6, Tsuneyo Mimori7, Tsutomu Takeuchi8, Shintaro Hirata9, Eiichi Tanaka10, Hidekata Yasuoka11, Yuko Kaneko8, Kosaku Murakami7, Tomohiro Koga12, Kazuhisa Nakano13, Koichi Amano14, Kazuyasu Ushio15, Tatsuya Atsumi16, Masayuki Inoo17, Kazuhiro Hatta18, Shinichi Mizuki19, Shohei Nagaoka20, Shinichiro Tsunoda21, Hiroaki Dobashi22, Nao Horie3 and Norihiro Sato3, 1University of Occupational and Environmental Health, Kitakyushu, Japan, 2Interfaculty Initiative in Information Studies, The University of Tokyo, Tokyo, Japan, 3Clinical Research and Medical Innovation Center, Hokkaido University Hospital, Sapporo, Japan, 4Hokkaido Medical Center for Rheumatic Diseases, Sapporo, Japan, 5NTT Sapporo Medical Center, Sapporo, Japan, 6Department of Medicine and Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan, 7Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 8Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 9Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan, 10Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 11Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, tokyo, Japan, 12Center for Bioinformatics and Molecular Medicine, Nagasaki University, Graduate School of Biomedical Sciences, Nagasaki, Japan, 13The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, 14Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, 15Ushio Clinic, Osaka, Japan, 16Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, 17Utazu hospital, Utatsu-cho, Japan, 18Department of General Medicine, Tenri Hospital, Tenri, Japan, 19Center for Rheumatic Diseases, Matsuyama Red Cross Hospital, Matsuyama, Japan, 20Department of Rheumatology, Yokohama Minami Kyosai Hospital, Yokohama, Japan, 21Division of Rheumatology Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan, 22Division of Endocrinology and Metabolism, Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Kagawa University, Miki-cho, Japan

    Background/Purpose: Infliximab (IFX), a TNF inhibitor, is one of the most widely used biological disease-modifying antirheumatic drugs. Recent studies indicated that baseline levels of serum…
  • Abstract Number: 2821 • 2018 ACR/ARHP Annual Meeting

    Dose Tapering and Discontinuation of Biological Therapy in Rheumatoid Arthritis Patients in Routine Care – 2-Year Outcomes and Predictors

    Cecilie Heegaard Brahe1, Simon Krabbe1, Mikkel Østergaard1, Lykke Midtbøll Ørnbjerg1, Daniel Glinatsi1, Henrik Rogind1, Hanne Slott Jensen2, Annette Hansen3, Jesper Nørregaard4, Søren Jacobsen5, Lene Terslev1, Tuan Khai Huynh4, Dorte Vendelbo Jensen6, Natalia Manilo2, Karsten Asmussen2, Per Brown-Frandsen5, Mikael Boesen7, Zoreh Rastiemadabadi7, Lone Morsel-Carlsen7, Jakob M. Møller8, Niels Steen Krogh9 and Merete Lund Hetland10, 1Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark, 2Center for Rheumatology and Spine Diseases, Bispebjerg-Frederiksberg Hospital, Copenhagen, Copenhagen, Denmark, 3Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Gentofte, Gentofte, Denmark, Copenhagen, Denmark, 4Center for Rheumatology and Spine Diseases, Nordsjællands Hospital, Hillerød, Denmark, Hillerød, Denmark, 5Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, 6Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Gentofte, Gentofte, Copenhagen, Denmark, 7Department of Radiology, Bispebjerg-Frederiksberg Hospital, Copenhagen, Copenhagen, Denmark, 8Department of Radiology, Copenhagen University Hospital Herlev, Copenhagen, Denmark, 9ZiteLab ApS, Copenhagen, Denmark, 10DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Glostrup, Denmark

    Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in routine care –  2-year outcomes and predictors   Background/Purpose: A cohort of routine care…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology